Market Research Industry Reports

The Medicines Company (MDCO) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

The Medicines Company (TMC) is a biopharmaceutical company, which provides medical solutions for improving health conditions in patients under critical care. The companys product portfolio comprises marketed products a peptide compound that inhibits an intravenous direct thrombin and needle-free patient-controlled system for short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital. Its pipeline products include an investigational anesthetic agent; and an investigational lipid-lowering drug. TMC also provides acute care generic pharmaceuticals products. The company offers its products for major therapeutic areas, which include surgery and perioperative care, acute care, and cardiovascular care. It has offices and other facilities in the US, the UK, Canada and other European countries. TMC is headquartered in Parsippany, New Jersey, the US.

The Medicines Company (MDCO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
The Medicines Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
The Medicines Company, Medical Devices Deals, 2012 to YTD 2018 10
The Medicines Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
The Medicines Company, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Medicines Company Exercises Option to Acquire Recothrom from Bristol-Myers Squibb for USD132 Million 13
Venture Financing 14
Annovation BioPharma Raises US$8 Million In Series A Financing 14
Annovation BioPharma Raises US$2 Million In Venture Financing 15
Partnerships 16
The Medicines Company Enters into Agreement with BARDA 16
Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 17
Licensing Agreements 18
SymBio Pharma Enters into Licensing Agreement with The Medicines Company 18
Medicines Company Enters into Licensing Agreement with SciClone 19
Medicines Company Enters Into Licensing Agreement With Bristol-Myers Squibb For Recothrom 21
Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 23
Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 25
Equity Offering 26
The Medicines Company Completes Public Offering Of Shares For US$201.3 Million 26
Debt Offering 27
The Medicines Company Raises USD 402.5 Million in Private Placement of 2.75% Notes Due 2023 27
Medicines Company Raises USD400 million in Private Placement of 2.5% Notes Due 2022 29
The Medicines Company Completes Private Placement Of Notes For US$275 Million 30
Asset Transactions 31
Melinta Therapeutics Acquires Infectious Disease Business Unit from The Medicines Company 31
Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 33
Mallinckrodt Acquires Three Topical Hemostasis Drugs from Medicines Company 35
Acquisition 37
Medicines Company Acquires Annovation Biopharma 37
Medicines Company Acquires Rempex Pharma For US$474 Million 38
Medicines Company Completes Acquisition Of ProFibrix For Up To US$240 Million 40
Medicines Company Completes Acquisition Of Incline Therapeutics For US$185 Million 42
The Medicines Company - Key Competitors 44
The Medicines Company - Key Employees 45
The Medicines Company - Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 48
Financial Announcements 48
Apr 25, 2018: The Medicines Company Reports First-Quarter 2018 Results 48
Feb 21, 2018: The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and Financial Results 50
Oct 25, 2017: The Medicines Company Reports Third-Quarter 2017 Business and Financial Results 52
Aug 09, 2017: The Medicines Company Reports Second Quarter 2017 Business and Financial Results 54
Apr 26, 2017: The Medicines Company Reports First-Quarter 2017 Financial Results 56
Feb 28, 2017: The Medicines Company Reports Fourth-Quarter and Full-Year 2016 Financial Results 57
Corporate Communications 59
Mar 27, 2018: The Medicines Company Announces Chief Financial Officer Transition 59
Feb 27, 2018: The Medicines Company Appoints Dr. Sarah Schlesinger to Its Board of Directors 60
Nov 15, 2017: The Medicines Company Names Dr. Fred Eshelman as Executive Chairman; Appoints Geno Germano to Its Board of Directors 61
Mar 31, 2017: The Medicines Company Appoints Paris Panayiotopoulos to Its Board of Directors 62
Clinical Trials 63
Apr 26, 2017: The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran 63
Mar 17, 2017: The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran 65
Mar 14, 2017: The Medicines Company to Webcast Presentation of ORION-1 Phase II Study of Inclisiran at ACC.17 67
Jan 25, 2017: The Medicines Company to Present Results from ORION-1 Phase 2 Study of Inclisiran at the American College of Cardiologys 66th Annual Scientific Session 68
Jan 08, 2017: The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran 69
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71

List Of Tables

List of Tables
The Medicines Company, Pharmaceuticals & Healthcare, Key Facts, 2017 2
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
The Medicines Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
The Medicines Company, Deals By Therapy Area, 2012 to YTD 2018 9
The Medicines Company, Medical Devices Deals, 2012 to YTD 2018 10
The Medicines Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Medicines Company Exercises Option to Acquire Recothrom from Bristol-Myers Squibb for USD132 Million 13
Annovation BioPharma Raises US$8 Million In Series A Financing 14
Annovation BioPharma Raises US$2 Million In Venture Financing 15
The Medicines Company Enters into Agreement with BARDA 16
Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 17
SymBio Pharma Enters into Licensing Agreement with The Medicines Company 18
Medicines Company Enters into Licensing Agreement with SciClone 19
Medicines Company Enters Into Licensing Agreement With Bristol-Myers Squibb For Recothrom 21
Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 23
Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 25
The Medicines Company Completes Public Offering Of Shares For US$201.3 Million 26
The Medicines Company Raises USD 402.5 Million in Private Placement of 2.75% Notes Due 2023 27
Medicines Company Raises USD400 million in Private Placement of 2.5% Notes Due 2022 29
The Medicines Company Completes Private Placement Of Notes For US$275 Million 30
Melinta Therapeutics Acquires Infectious Disease Business Unit from The Medicines Company 31
Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 33
Mallinckrodt Acquires Three Topical Hemostasis Drugs from Medicines Company 35
Medicines Company Acquires Annovation Biopharma 37
Medicines Company Acquires Rempex Pharma For US$474 Million 38
Medicines Company Completes Acquisition Of ProFibrix For Up To US$240 Million 40
Medicines Company Completes Acquisition Of Incline Therapeutics For US$185 Million 42
The Medicines Company, Key Competitors 44
The Medicines Company, Key Employees 45
The Medicines Company, Subsidiaries 46

List Of Figures

List of Figures
The Medicines Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
The Medicines Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
The Medicines Company, Medical Devices Deals, 2012 to YTD 2018 10

Agile Therapeutics Inc (AGRX) - Medical Equipment - Deals and Alliances Profile

Agile Therapeutics Inc (Agile) is a healthcare company that develops and commercializes prescription contraceptive products for women. The company provides contraceptive patch containing the active ingredients levonorgestrel and ethinyl estradiol

USD 250View Report

C3J Therapeutics Inc - Pharmaceuticals and Healthcare - Deals and Alliances Profile

C3J Therapeutics Inc (C3J), formerly C3 Jian Inc is a clinical-stage biotechnology company that offers discovery and development of novel targeted antimicrobials, synthetic bacteriophage and antimicrobial peptides. Its pipeline products

USD 250View Report

The Medicines Company Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

The Medicines Company Company Profile is a detailed strategic and analytical report on The Medicines Company. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200View Report

The Medicines Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

The Medicines Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines The Medicines Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description,

USD 350View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Jul 2018
No. of Pages :71
Country :United States of America
Category :Company Profiles
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube